Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab plus CHOP-14 versus CHOP-14 with autologous transplant in untreated peripheral T-cell lymphoma
NL-OMON31642Phase 3Not yet recruiting
- Sponsor
- Nordic Lymphoma Group
- Start
- May 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of alemtuzumab in peripheral T-cell lymphoma (PTCL) and T-cell lymphoma, sponsored by Nordic Lymphoma Group. Planned start May 2008; status: not yet recruiting.
02
Drugs
alemtuzumab
03
Conditions
peripheral T-cell lymphoma (PTCL)T-cell lymphoma
Beyond the preview
Go deeper on NL-OMON31642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31642.